SCHEMBL3574502

SCHEMBL3574502

COCCN(Cc1ccc(Br)cc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 4/20 0.52
HDAC6 Q9UBN7 4/20 0.52
TDP1 Q9NUW8 1/20 0.48
KDM4E B2RXH2 1/20 0.48
GLA P06280 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
FPR3 P25089 1/20 0.41
FPR2 P25090 1/20 0.41
MLYCD O95822 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
NPC1 O15118 1/20 0.40
THRB P10828 1/20 0.40
RAB9A P51151 1/20 0.40
FOLH1 Q04609 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22804425 0.88 TAAR1 (0.46) HDAC1HDAC6TDP1KDM4EGLA
SCHEMBL3615501 0.86 HDAC1 (0.46) HDAC1HDAC6TDP1KDM4EGLA
SCHEMBL3571606 0.84 PTGES (0.55) HDAC1HDAC6KDM4EMEN1KMT2A
SCHEMBL13166745 0.83 HDAC1 (0.45) HDAC1HDAC6TDP1KDM4EGLA
SCHEMBL2846916 0.83 HDAC1 (0.46) HDAC1HDAC6MEN1KMT2ASMN1; SMN2
SCHEMBL408156 0.80 HDAC1 (0.47) HDAC1HDAC6TDP1KDM4EGLA
SCHEMBL2104567 0.79 CRHBP (0.54) HDAC1HDAC6L3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL25419439 0.78 LSS (0.38) HDAC1HDAC6MEN1KMT2ASMN1; SMN2
SCHEMBL3563248 0.77 HDAC1 (0.46) HDAC1HDAC6KDM4EMEN1KMT2A
SCHEMBL1239426 0.76 KDM4E (0.59) TDP1KDM4EGLAL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904504-B1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC (CA) 2014-03-19 EP disclosed
EP-1781664-B1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC (CA) 2013-09-04 EP disclosed
US-8470850-B2 Inhibitors of VEGF receptor and HGF receptor signalling METHYLGENE INC. (CA) 2013-06-25 US disclosed
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 US disclosed
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling 92229129 QUEBEC INC. (CA) 2010-08-26 US disclosed
US-7772247-B2 Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor METHYLGENE INC. (CA) 2010-08-10 US disclosed
US-20060287343-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. 2006-12-21 US disclosed
US-20060074056-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. (CA) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074056-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 HDAC1 1373/4885HDAC6 671/4885TDP1 4530/4885
US-20060287343-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING HGF, MET, FLT1 HDAC1 1373/4885HDAC6 671/4885TDP1 4530/4885
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling HGF, MET, FLT1 HDAC1 1373/4885HDAC6 671/4885TDP1 4530/4885
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling HGF, MET, FLT1 HDAC1 1427/4885HDAC6 677/4885TDP1 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.